Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

计划入组 20 人 · 首次发布于 2019 年 6 月 17 日

Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma

计划入组 1,800 人 · 首次发布于 2016 年 9 月 20 日

Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma

计划入组 150 人 · 首次发布于 2024 年 6 月 26 日

neoantigen loaded dendritic cell vaccine (sc, esophageal squamous cell carcinoma)

NANT Squamous Cell Carcinoma Vaccine

GPR87 antagonists (squamous cell carcinoma)

Gamida Cell

Israel

GAMIDA CELL INC.

United States

CELL GENESYS INC.

United States

Tislelizumab Approved in Israel for Advanced Esophageal Squamous Cell Carcinoma

CheckMate 648 and KEYNOTE-590 Establish Chemo-Immunotherapy as First-Line Standard for Advanced Esophageal Squamous Cell Carcinoma

UK Approves Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma